An analysis of patients with suspected sepsis at US hospitals found that antibiotic de-escalation was infrequent and varied ...

Collections of Medscape's key clinical content, selected by our editors ...

U.S. total addressable market for five initial indications is $25 to $33 billionREMINDER: Business Update Conference Call begins at 4:30 p.m.

The presentation highlights XORTX recent pioneering discoveries in the field of Autosomal Dominant Polycystic Kidney Disease ...

Vital signs including intake and output, and laboratory data should be carefully observed to monitor for the risk or appearance of sepsis and septic ... and hepatic or renal panels, must be ...

Clinicians treating patients with kidney disease must be aware of dental considerations to avoid potentially lethal consequences.

AstraZeneca's supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive ...

Progress in assessing cardiovascular risk and identifying early prevention opportunities, improvements in treating heart ...

Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377] Draft guidance Technology appraisal guidance 10 January 2025 Cladribine for ...

Baxter International Inc. , a global leader in injectables, anesthesia and drug compounding, today announced five new injectable pharmaceutical product launches in the U.S., joining the previous five ...

Hydrocele and varicocele are two conditions affecting the external male genitalia. Hydrocele is the swelling of the scrotum ...